Wedbush Comments on AnaptysBio's Q3 Earnings (NASDAQ:ANAB)

Key Points

• Wedbush analysts have increased their Q3 2025 earnings per share estimate for AnaptysBio from ($1.70) to ($0.85), maintaining an "Outperform" rating with a target price of $45.00.
• AnaptysBio reported earnings of ($1.34) EPS for its latest quarter, surpassing expectations of ($1.50) EPS, and achieved a revenue of $22.26 million, significantly above the consensus estimate of $11.55 million.
• Several brokerages have raised their target prices for AnaptysBio, with Guggenheim increasing theirs to $90.00 and JPMorgan Chase & Co. lifting theirs to $80.00, indicating strong investor sentiment and interest in the stock.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Wedbush boosted their Q3 2025 EPS estimates for shares of AnaptysBio in a research note issued to investors on Thursday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($0.85) per share for the quarter, up from their previous estimate of ($1.70). Wedbush has a "Outperform" rating and a $45.00 price objective on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio's Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($4.27) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.24) EPS, FY2027 earnings at ($1.39) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($0.71) EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

Several other research analysts have also commented on ANAB. UBS Group restated a "neutral" rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday. Guggenheim restated a "buy" rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and increased their price target for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Finally, JPMorgan Chase & Co. increased their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $46.13.

AnaptysBio Price Performance

AnaptysBio stock traded up $0.89 during trading hours on Monday, hitting $21.00. The company had a trading volume of 534,849 shares, compared to its average volume of 774,061. The firm's fifty day moving average is $24.09 and its 200-day moving average is $20.52. AnaptysBio has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The firm has a market capitalization of $587.96 million, a P/E ratio of -4.74 and a beta of -0.20.

Institutional Trading of AnaptysBio

A number of hedge funds have recently bought and sold shares of ANAB. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio in the 4th quarter valued at $40,000. Vanguard Group Inc. boosted its holdings in AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after purchasing an additional 143,584 shares during the period. JPMorgan Chase & Co. boosted its holdings in AnaptysBio by 240.6% in the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock valued at $1,522,000 after purchasing an additional 81,195 shares during the period. Geode Capital Management LLC boosted its holdings in AnaptysBio by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock valued at $6,444,000 after purchasing an additional 21,196 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in AnaptysBio by 1,585.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 5,360 shares during the period.

Insider Activity

In related news, Director Hollings Renton sold 20,925 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares of the company's stock, valued at approximately $117,025.05. This represents a 80.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 33.50% of the company's stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.